Risk grade updatedRisk gradeEvidence verified
21 Oct 2026 · BUSINESS.fi / Opterom LuottoluokitusAutomatic grade B2.Business profile
Orifarm Oy
Orifarm Oy's registered office is Esbo. It is a limited company. The company was established on 1998-06-01. It operates in the industry of wholesale of pharmaceutical goods. In its latest retained statement for 2025-12-31, revenue was €35,991,621 and operating profit was €447,211.
Business ID 1479981-0ValidUnclaimed company profile
Trusted core data
Public company details from the trade register.
- Business ID
- 1479981-0
- Sector
- Wholesale of pharmaceutical goods
- Municipality
- Esbo
- Company form
- Limited company
- Registration date
- 1998-06-01
- Business ID registration date
- 1998-08-04
- Business status
- Valid
- Profile ownership
- Unclaimed company profile
Contact and location summary
Visiting address: Metsänneidonkuja 12, 02130, Esbo
Phone: +3588007077000Source observation
Email: [email protected]Source observation
Website: https://www.orifarm.comSource observation
Youtube profile: https://www.youtube.com/@orifarm7943Source: company website
Linkedin profile: https://www.linkedin.com/company/orifarm?originalSubdomain=dkSource: company website
People and decision-makers
Raappana Sanna JohannaToimitusjohtaja
About Orifarm Oy
Financial position and key figures for the company.
Orifarm Oy's location municipality is Esbo. It is a limited company. The company was established on 1998-06-01. It operates in the industry of wholesale of pharmaceutical goods. In its latest retained statement for 2025-12-31, revenue was €35,991,621 and operating profit was €447,211. The latest retained financial statement for 2025-12-31 shows revenue of €35,991,621 and profit for the financial year of €210,604. Based on the latest retained statement, revenue growth was -1.7%, operating margin was +1.2%, and equity ratio was +12.2%.
Extended business activity
A longer directory- or registry-backed activity description that complements the short registry industry label.
Bolagets verksamhetsområde är import och export av samt handel med läkemedel och övriga hälsovårdsprodukter.
Financial highlights
Key figures from the latest financial period.
Latest financial period
2025-12-31
0
0
Source observation
Derived indicators
Revenue growth-1.7%
Operating margin1.2%
Equity ratio12.2%
Revenue€35,991,621-€625,005 (-1.7%) vs previous periodPrevious: €36,616,626
Operating profit (loss)€447,211-€49,284 (-9.9%) vs previous periodPrevious: €496,495
Profit (loss) for the financial year€210,604+€43,343 (+25.9%) vs previous periodPrevious: €167,261
Assets€5,344,241-€1,920,477 (-26.4%) vs previous periodPrevious: €7,264,718
Balance-sheet contextLatest financial period
Employees7Previous: 7
Revenue trend4 periods
€35,981,824
2022-12-31
€33,164,026
2023-12-31
€36,616,626
2024-12-31
€35,991,621
2025-12-31
Operating profit (loss) trend4 periods
€359,819
2022-12-31
€293,125
2023-12-31
€496,495
2024-12-31
€447,211
2025-12-31
Profit (loss) for the financial year trend4 periods
€127,179
2022-12-31
€137,456
2023-12-31
€167,261
2024-12-31
€210,604
2025-12-31
Assets trend4 periods
€7,754,966
2022-12-31
€8,987,918
2023-12-31
€7,264,718
2024-12-31
€5,344,241
2025-12-31
Additional financial figures
The company's financial figures across different years.
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | - | €35,991,621 | €36,616,626 | €33,164,026 | €35,981,824 |
| Revenue growth | - | -1,7 % | 10,4 % | -7,8 % | -25,1 % |
| Operating profit | - | €447,211 | €496,495 | €293,125 | €359,819 |
| EBIT margin | - | 1,2 % | 1,4 % | 0,9 % | 1 % |
| Profit for the financial year | - | €210,604 | €167,261 | €137,456 | €127,179 |
| Profit before taxes | - | - | - | €176,239 | €161,913 |
| Equity ratio | - | 12,2 % | 6 % | 19,7 % | 21,1 % |
| Balance sheet total | - | €5,344,241 | €7,264,718 | €8,987,918 | €7,754,966 |
| Employees | 7 | 7 | 7 | 7 | 7 |
Financial ratios
Financial ratios based on financial statement data. Source: Lähdehavainto.
Equity ratioWeak
15/100 · Improving
Current ratioNot assessable
0/100 · Trend unavailable
Operating profit marginPassable
53/100 · Declining
Ratio history
| Ratio | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Equity ratio | 21.1 % | 19.7 % | 6.0 % | 12.2 % |
| Current ratio | - | - | - | - |
| Operating profit margin | 1.0 % | 0.9 % | 1.4 % | 1.2 % |
Registry status and identifiers
Current registry information and identifiers based on YTJ data.
YTJ statusValid
Trade RegisterRegistered
Business ID1479981-0
VAT IDFI14799810
EU IDFIFPRO.1479981-0
MunicipalityEsbo
Current registered entries
1998-06-01Registered in Patent and Registration Office (Trade Register)
1998-08-04Registered in Tax Administration (Tax Administration)
2000-10-01Registered in Tax Administration (Employer Register)
2004-04-01VAT-liable for business activity in Tax Administration (VAT Register)
2004-05-01Registered in Tax Administration (Prepayment Register)
Responsible people
Public role relationships materialized from source observations.
Raappana Sanna JohannaToimitusjohtajaSources: 5 · Confidence: 78%
Hans Bøgh-SørensenHallitus: puheenjohtajaSources: 1 · Confidence: 76%
Hans CarlHallituksen puheenjohtajaSources: 1 · Confidence: 74%
Robert KajanderPäävastuullinen tilintarkastajaSources: 1 · Confidence: 76%
Risk certificate
An open-data based company stability and risk signal.
BUSINESS.fi
BUSINESS.fi Luottoluokitus
Profile-specific risk signal based on open data
Automatic gradeNot a credit decision
B2
SatisfactoryOrifarm Oy
Grade downgradedB1 → B2 · new analysis 2026-10-21
55/100
Medium
Usable financial evidenceFinancial data included
Financial development is mostly stable or mixed.
4 comparable periodsRevenueImproving
ProfitabilityStable
SolvencyVolatile
LiquidityNot enough history
Same industryDescriptive comparison – does not change the model score.
185 peersSolvency22%
Below 78% of peers
Profitability48%
Close to the peer-group midpoint
Revenue growth35%
Below 65% of peers
Supporting factors
- Active registered status
- A newer financial statement filing has been reported
- Long registry continuity
Risk factors to note
- Elevated industry distress context
Automatic assessment developmentChanges are derived from evidence differences between persisted automatic assessments.
2 assessmentsB2
2026-10-2155/100 · v0.15
B1 → B2 · -14 points- Revenue: Not enough history → Improving
- Profitability: Not enough history → Stable
- Solvency: Not enough history → Volatile
B1
2026-09-2469/100 · v0.14
Oldest retained automatic assessment in this comparisonB2
2026-10-21
open-risk-grade-v0.15
The grade can use open digital financial statement data together with registry signals.
Risk context
When sufficient source-backed financial metrics are not available for a Tier 1 assessment, BUSINESS.fi shows registry, industry, and regional context.
Industry riskelevated
45/100
Industry context is elevated based on normalized open statistical inputs.
Age and continuityVakiintunut
90/100
The company has about 28 years of registry continuity.
Registry and status signalsVakaa
84/100
Registry history, filing recency, and active register markings are still limited or mixed.
Events & news
Verified events and sourced external company news in one timeline.
Risk grade updatedRisk gradeEvidence verified
24 Sept 2026 · BUSINESS.fi / Opterom LuottoluokitusAutomatic grade B1.Registry timeline
Trade register notifications shown on a timeline.
21 register eventsLatest event: 2026-07-04
Profile source and ownership
Profile based on public registry data
BUSINESS.fi has created this profile from public company information. Source data updated 2025-12-31.
This company profile has not been claimed yet
Orifarm Oy shows public core facts. A company representative can claim the profile, update public information, and access owner tools.